Results for: Gyn

10 Trials Avaliable

  • GYN 102

    Available in 15 location(s)

  • GYN 107

    A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary EfficacyStudy of STRO-002, an Anti-Folate Receptor alpha (FolRa) Antibody DrugConjugate (ADC), in Combination with Bevacizumab in Patients withAdvanced Epithelial Ovarian Cancer (Including Fallopian Tube or PrimaryPeritoneal Cancers)

    Available in 16 location(s)

  • GYN 108

    A PHASE 1b STUDY OF ZN-c3 IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER

    Available in 15 location(s)

  • GYN 110

    AN OPEN-LABEL, MULTICENTER, DOSEESCALATION AND EXPANSION MODULAR,UMBRELLA MASTER STUDY OF UPIFITAMABRILSODOTIN IN COMBINATION WITH OTHERAGENT(S) IN PARTICIPANTS WITH HIGH-GRADESEROUS OVARIAN CANCER (UPGRADE)

    Available in 15 location(s)

  • GYN 114

    An Open-Label, Phase 1b Study of SL-172154 (SIRPa-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers

    Available in 16 location(s)

  • GYN 115

    Available in 17 location(s)

  • GYN 116

    A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

    Available in 17 location(s)

  • GYN 81

    A Phase 1/2 Study of REGN4018 Administered Alone or in Combination with Cemiplimab in Patients with Platinum-Resistant Ovarian Cancer

    Available in 16 location(s)

  • GYN 88

    A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolR?) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

    Available in 1 location(s)

  • GYN 99

    An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

    Available in 15 location(s)